Stifel Nicolaus restated their buy rating on shares of Cooper Companies (NYSE:COO) in a research report sent to investors on Friday. Stifel Nicolaus currently has a $265.00 price objective on the medical device company’s stock, down from their previous price objective of $275.00.

A number of other brokerages also recently weighed in on COO. Robert W. Baird reissued a buy rating and set a $273.00 target price (up previously from $267.00) on shares of Cooper Companies in a research note on Tuesday, September 12th. Zacks Investment Research raised shares of Cooper Companies from a hold rating to a buy rating and set a $277.00 target price for the company in a research note on Tuesday, August 29th. Jefferies Group set a $250.00 target price on shares of Cooper Companies and gave the stock a buy rating in a research note on Thursday, August 17th. Oppenheimer reissued a hold rating and set a $250.00 target price on shares of Cooper Companies in a research note on Tuesday, September 12th. Finally, Cleveland Research reissued a buy rating on shares of Cooper Companies in a research note on Tuesday, August 22nd. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $259.70.

Shares of Cooper Companies (NYSE COO) traded down $12.24 during midday trading on Friday, reaching $226.56. 1,372,152 shares of the company were exchanged, compared to its average volume of 328,467. Cooper Companies has a fifty-two week low of $168.00 and a fifty-two week high of $256.39. The company has a market capitalization of $11,689.08, a P/E ratio of 24.57, a PEG ratio of 1.99 and a beta of 0.54. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.51 and a quick ratio of 1.29.

Cooper Companies (NYSE:COO) last announced its earnings results on Thursday, December 7th. The medical device company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.01. Cooper Companies had a net margin of 17.43% and a return on equity of 16.33%. The business had revenue of $561.50 million during the quarter, compared to the consensus estimate of $558.86 million. During the same quarter last year, the firm earned $2.28 earnings per share. Cooper Companies’s quarterly revenue was up 8.3% on a year-over-year basis. analysts anticipate that Cooper Companies will post 11.17 earnings per share for the current year.

In other Cooper Companies news, Director Gary S. Petersmeyer sold 3,977 shares of Cooper Companies stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $244.94, for a total value of $974,126.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Advisory Services Network LLC increased its stake in Cooper Companies by 30.6% in the second quarter. Advisory Services Network LLC now owns 457 shares of the medical device company’s stock valued at $109,000 after purchasing an additional 107 shares in the last quarter. YorkBridge Wealth Partners LLC increased its position in shares of Cooper Companies by 2.1% during the second quarter. YorkBridge Wealth Partners LLC now owns 531 shares of the medical device company’s stock worth $126,000 after acquiring an additional 11 shares in the last quarter. Acrospire Investment Management LLC increased its position in shares of Cooper Companies by 50.0% during the second quarter. Acrospire Investment Management LLC now owns 600 shares of the medical device company’s stock worth $144,000 after acquiring an additional 200 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Cooper Companies during the third quarter worth about $163,000. Finally, Penserra Capital Management LLC increased its position in shares of Cooper Companies by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the medical device company’s stock worth $211,000 after acquiring an additional 102 shares in the last quarter. 96.79% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Cooper Companies’ (COO) Buy Rating Reaffirmed at Stifel Nicolaus” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.watchlistnews.com/cooper-companies-coo-buy-rating-reaffirmed-at-stifel-nicolaus/1754378.html.

About Cooper Companies

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.